Bendamustine: A review of its use in the management of chronic lymphocytic leukaemia, rituximab-refractory indolent non-hodgkins lymphoma and multiple myeloma

Drugs

Volumn 72, Issue 14, 2012, Pages 1929-1950

  Hoy, Sheridan M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Evaluations; Bendamustine; Chlorambucil; Chronic lymphocytic leukaemia; Melphalan; Multiple myeloma; Non Hodgkins lymphoma; Pharmacokinetics; Pharmacology; Prednisone

Indexed keywords

BENDAMUSTINE; BORTEZOMIB; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; LENALIDOMIDE; MELPHALAN; PENTOSTATIN; PREDNISONE; RITUXIMAB; TACROLIMUS; THALIDOMIDE;

ANEMIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLOOD TOXICITY; BULLOUS SKIN DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER REGRESSION; CARDIOTOXICITY; CHRONIC LYMPHATIC LEUKEMIA; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EUROPEAN UNION; FATIGUE; FEVER; FOLLOW UP; HERPES ZOSTER; HUMAN; INFECTION; LEUKOPENIA; LYMPHOCYTOPENIA; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECOMMENDED DRUG DOSE; REVIEW; RISK BENEFIT ANALYSIS; RITUXIMAB REFRACTORY INDOLENT NON HODGKIN LYMPHOMA; SENSORY NEUROPATHY; SKIN ALLERGY; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; VOMITING;

ANTINEOPLASTIC AGENTS, ALKYLATING; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, NON-HODGKIN; MULTIPLE MYELOMA; NITROGEN MUSTARD COMPOUNDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES;

EID: 84866086236     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11209510-000000000-00000     Document Type: Review

References (46)

1. National Institute for Clinical Excellence. Guidance on cancer services: improving outcomes in haematological cancers [online]. Available from URL: http://www.nice. org.uk/nicemedia/pdf/NICE-HAEMATOLOGICAL-CSG. pdf [Accessed 2012 Jul 27]
2. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: non-Hodgkin's lymph-omas. 3.2012 [online]. Available from URL: http://www. nccn.org/professionals/physician-gls/pdf/nhl.pdf [Accessed 2012 Jul 27]
3. Cheson BD, Rummel MJ. Bendamustine: rebirth of an old drug. J Clin Oncol 2009; 27 (9): 1492-501
4. Scott LJ, Lyseng-Williamson KA. Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma. Drugs 2011; 71 (5): 625-49
5. Napp Pharmaceuticals Limited. Levact 2.5mg/ml powder for concentrate for solution for infusion: summary of product characteristics [online]. Available from URL: http://www.medicines.org.uk/EMC/medicine/23469/SPC/Levact+ 2.5+mg+ml+powder+for+concentrate+for+solution+for+ infusion/[Accessed 2012 Jul 27]
6. Cephalon Inc. Treanda® (bendamustine hydrochloride for injection) for intravenous infusion: US prescribing information [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/022249s006lbl. pdf [Accessed 2012 Jul 27]
7. Barman Balfour JA, Goa KL. Bendamustine. Drugs 2001; 61 (5): 631-8; discussion 639-40 (Pubitemid 32454528)
8. Plosker GL, Carter NJ. Bendamustine: a review of its use in the management of indolent non-Hodgkin lymphoma. Drugs 2008; 68 (18): 2645-60
9. Garnock-Jones KP. Bendamustine: a review of its use in the management of indolent non-Hodgkin's lymphoma and mantle cell lymphoma. Drugs 2010; 70 (13): 1703-18
10. Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008; 14 (1): 309-17 (Pubitemid 351378007)
11. Napp Pharmaceuticals Limited. Levact® i.v. (bendamustine HCl): product monograph [online]. Available from URL: http://www.napponcology.co.uk/- pdfs/Levact%20product %20monograph%20March%202011.pdf [Accessed 2012 Jul 27]
12. Leoni LM, Hartley JA. Mechanism of action: the unique pattern of bendamustine-induced cytotoxicity. Semin He-matol 2011; 48 (2 Suppl. 1): S12-23
13. Leoni LM. Bendamustine: rescue of an effective antineoplastic agent from the mid-twentieth century. Semin Hematol 2011; 48 (2 Suppl. 1): S4-11
14. Beeharry N, Rattner JB, Bellacosa A, et al. Dose dependent effects on cell cycle checkpoints and DNA repair by bendamustine. PLoS One 2012 Jun; 7 (6): e40342
15. Roue G, Lopez-Guerra M, Milpied P, et al. Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling. Clin Cancer Res 2008 Nov; 14 (21): 6907-15
16. Teichert J, Baumann F, Chao Q, et al. Characterization of two phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochloride. Cancer Chemother Pharmacol 2007; 59: 759-70 (Pubitemid 46440598)
17. Owen JS, Melhem M, Passarell JA, et al. Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma. Cancer Chemother Pharmacol 2010; 66 (6): 1039-49
18. Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer 2010; 116 (1): 106-14
19. Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlo-rambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009; 27 (26): 4378-84
20. Knauf WU, Lissitchkov T, Aldaoud A, et al. Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial. Br J Haematol. Epub 2012 Aug 4
21. Knauf WU, Lissitchkov T, Aldaoud A, et al. Bendamustine in the treatment of chronic lymphocytic leukemia: consistent superiority over chlorambucil in elderly patients and across clinically defined risk groups [abstract no. 2367 plus poster]. 51st Annual Meeting and Exposition of the American Society of Hematology; 2009 Dec 5-8; New Orleans (LA)
22. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996 Jun; 87 (12): 4990-7 (Pubitemid 26189840)
23. Woods B, Hawkins N, Dunlop W, et al. Bendamustine versus chlorambucil for the first-line treatment of chronic lymphocytic leukemia in England and Wales: a cost-utility analysis. Value Health 2012; 15 (5): 759-70
24. Holtzer-Goor K, Vandekerckhove S, van den Steen D, et al. Modelling the 10-year cost effectiveness of bendamustine as first line treatment for chronic lymphocytic leukaemia in the Netherlands [abstract no. 1089 plus poster]. Haemato-logica 2012 Jun; 97 Suppl. 1: 443
25. Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study [published erratum appears in J Clin Oncol 2008 Apr; 26 (11): 1911]. J Clin Oncol 2008 Jan; 26 (2): 204-10
26. Cheson BD, Friedberg JW, Kahl BS, et al. Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leukemia 2010; 10 (6): 452-7
27. Cheson BD, Friedberg JW, Kahl, BS, et al. Bendamustine produces durable responses with an acceptable long-term safety profile in patients with rituximab-refractory non-Hodgkin's lymphoma: a pooled analysis [poster no. II-657]. 51st American Society of Hematology Annual Meeting and Exposition; 2009 Dec 5-8; New Orleans (LA)
28. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999 Apr; 17 (4): 1244-53 (Pubitemid 29162950)
29. Ponisch W, Mitrou PS, Merkle K, et al. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone: a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol 2006; 132 (4): 205-12 (Pubitemid 43144255)
30. Durie BG, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975 Sep; 36 (3): 842-54
31. Alexanian R, Bonnet J, Gehan E, et al. Combination chemotherapy for multiple myeloma. Cancer 1972 Aug; 30 (2): 382-9
32. Peest D, Coldewey R, Deicher H, et al. Prognostic value of clinical, laboratory, and histological characteristics in multiple myeloma: improved definition of risk groups. Eur J Cancer 1993; 29A (7): 978-83 (Pubitemid 23126695)
33. Peest D, Deicher H, Coldewey R, et al. A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma: a prospective trial of the German Myeloma Treatment Group. Eur J Cancer 1995; 31A (2): 146-51
34. Cheson BD, Kroll ML. Bendamustine induced neurotoxicity. Clin Adv Hematol Oncol 2009 Nov; 7 (11): 743-6
35. European Medicines Agency. Questions and answers on Levact and associated names (bendamustine hydro-chloride, 2.5 mg/ml, powder for concentrate for solution for infusion) [online]. Available from URL: http://www. ema.europa.eu/docs/en-GB/document-library/Referrals- document/Levact-29/ WC500075906.pdf [Accessed 2012 Jul 27]
36. Eichhorst B, Dreyling M, Robak T, et al. Chronic lymphocytic leukemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011 Sep; 22 Suppl. 6: vi50-4
37. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008 Jun; 111 (12): 5446-56
38. Faderl S, Ferrajoli A, Frankfurt O, et al. Treatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapy. Leukemia 2009 Mar; 23 (3): 457-66
39. Cheson BD, Ashforth E. Newer strategies for overcoming rituximab resistance in non-Hodgkins lymphoma and chronic lymphocytic leukemia. Clin Adv Hematol Oncol 2009; 7 (2 Suppl. 5): 8-16
40. Dreyling M, Ghielmini M, Marcus R, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011 Sep; 22 Suppl. 6: vi59-63
41. European Medicines Agency. Levact. Article 29 referral. Annex I, II, III, IV [online]. Available from URL: http://www.ema.europa.eu/docs/en-GB/document- library/Refer rals-document/Levact-29/WC500111589.pdf [Accessed 2012 Jul 27]
42. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: multiple myeloma. 1.2012 [online]. Available from URL: http://www.nccn.org/pro fessionals/physician-gls/pdf/myeloma.pdf [Accessed 2012 Jul 27]
43. Harousseau J-L, Dreyling M. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010 May; 21 Suppl. 5: v155-7
44. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) guideline on the evaluation of anticancer medicinal products in man [online]. Available from URL: http://www.ema.europa.eu/docs/en-GB/document- library/Scientific-guideline/2009/12/WC500017748. pdf [Accessed 2012 Jul 27]
45. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): updated results from the StiL NHL1 study [abstract no. 3]. J Clin Oncol 2012 Jun; 30 Suppl.
46. Cheson BD, Wendtner C-M, Pieper A, et al. Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk 2010 Feb; 10 (1): 21-7